Skip to main content
Loading…

Chamber and committees

Questions and answers

Parliamentary questions can be asked by any MSP to the Scottish Government or the Scottish Parliamentary Corporate Body. The questions provide a means for MSPs to get factual and statistical information.

  • Written questions must be answered within 10 working days (20 working days during recess)
  • Other questions such as Topical, Portfolio, General and First Minister's Question Times are taken in the Chamber

Urgent Questions aren't included in the Question and Answers search.  There is a SPICe fact sheet listing Urgent and emergency questions.

Find out more about parliamentary questions

Filter your results Hide all filters

Dates of parliamentary sessions
  1. Session 1: 12 May 1999 to 31 March 2003
  2. Session 2: 7 May 2003 to 2 April 2007
  3. Session 3: 9 May 2007 to 22 March 2011
  4. Session 4: 11 May 2011 to 23 March 2016
  5. Session 5: 12 May 2016 to 4 May 2021
  6. Session 6: 13 May 2021 to 8 April 2026
  7. Current session: 7 May 2026 to 8 May 2027
Answer status
Question type

Displaying 1316 questions Show Answers

Order by |

Question reference: S6W-29756

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Tuesday, 10 September 2024
  • Current Status: Answered by Neil Gray on 19 September 2024

To ask the Scottish Government, in relation to its decision to pause the replacement of St Brendan’s hospital in Castlebay; whether it has held any recent meetings with NHS Western Isles, and, if so, whether it can provide details of what was discussed.

Question reference: S6W-29757

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Tuesday, 10 September 2024
  • Current Status: Answered by Neil Gray on 19 September 2024

To ask the Scottish Government what its response is to reports that the air flow cleansing canopy in an NHS Western Isles operating theatre is showing signs of failure, but that this work is reportedly unaffordable in the current financial year.

Question reference: S6W-29684

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government which NHS boards prescribe ocrelizumab (Ocrevus) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.

Question reference: S6W-29629

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Siobhian Brown on 18 September 2024

To ask the Scottish Government whether it carried out an Island Communities Impact Assessment in advance of the reported end of grant funding agreements for advice services in the Western Isles on 31 March 2024, and, if this is not the case, for what reason.

Question reference: S6W-29681

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government which NHS boards prescribe fingolimod (Gilenya) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.

Question reference: S6W-29680

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government which NHS boards prescribe diroximel fumarate (Vumerity) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.

Question reference: S6W-29688

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government which NHS boards prescribe Rebif (beta interferon-1a) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.

Question reference: S6W-29678

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government which NHS boards prescribe cladribine (Mavenclad) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.

Question reference: S6W-29685

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government which NHS boards prescribe ozanimod (Zeposia) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.

Question reference: S6W-29682

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government which NHS boards prescribe glatiramer acetate (Copaxone) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.